Plasma Cell Neoplasms: Multiple Myeloma, MGUS, and Plasmacytoma — Overview, Diagnosis & Treatment Options | MyMedicPlus

Plasma cell neoplasms are a spectrum of clonal B-cell disorders characterized by the abnormal proliferation of terminally differentiated antibody-producing plasma cells, with consequent secretion of a monoclonal immunoglobulin or its fragments (M-protein, M-spike, or light chains). The spectrum ranges from the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) through smoldering (asymptomatic) multiple myeloma to symptomatic multiple myeloma (MM), solitary plasmacytoma of bone, and extramedullary plasmacytoma. Multiple myeloma is the most clinically significant entity, representing approximately 10% of hematologic malignancies with approximately 35,000 new cases diagnosed per year in the United States. The disease predominantly affects adults in the sixth and seventh decades and is more common in men and in African American populations (approximately 2-fold higher incidence versus white Americans). Modern treatment has dramatically improved median OS from approximately 3 years in the pre-bortezomib era to over 7-8 years with current quadruplet induction regimens, autologous SCT, and novel maintenance strategies.

MGUS is the universal recognizable precursor to multiple myeloma, progressing to myeloma at a rate of approximately 1% per year. Risk factors for MGUS and myeloma include advanced age (median age of myeloma diagnosis is 69 years), African American ethnicity (2-fold higher incidence), male sex, a positive family history of plasma cell or lymphoid neoplasms, obesity, and agricultural chemical exposure. High-risk genomic features at diagnosis define therapeutic intensity: del(17p13) involving the TP53 locus, t(4;14) causing FGFR3 and MMSET overexpression, t(14;16) and t(14;20) involving MYC dysregulation, and gain of chromosome arm 1q (gain(1q)) are all associated with inferior prognosis and require intensified therapy. Hyperdiploid myeloma (odd-number chromosome trisomies) and t(11;14) (venetoclax-sensitive) represent more favorable genomic subtypes. Secondary myeloma arising after lymphoma treatment (alkylating agents, radiation) is documented but rare.

Symptomatic myeloma is defined and distinguished from smoldering myeloma by the presence of one or more myeloma-defining events, summarized in the CRAB criteria or SLiM criteria. CRAB features: hyperCalcemia (serum calcium greater than 11 mg/dL or more than 1 mg/dL above the upper limit of normal); Renal insufficiency (creatinine above 2 mg/dL or creatinine clearance below 40 mL/min, often from cast nephropathy caused by free light chains); Anemia (hemoglobin below 10 g/dL from bone marrow suppression and EPO deficiency); and Bone disease (lytic lesions, pathological fractures, or osteoporosis with compression fractures). SLiM criteria (60% or more bone marrow plasma cells, involved/uninvolved serum free light chain ratio above 100, or more than 1 focal lesion on MRI) mandate treatment even without CRAB features. Additional manifestations include profound fatigue, recurrent bacterial infections from hypogammaglobulinemia (opsonization defects predisposing to pneumococcal and Haemophilus infections), peripheral neuropathy from AL amyloidosis, and hyperviscosity syndrome with visual changes and bleeding.

Diagnostic workup includes serum protein electrophoresis (SPEP) with immunofixation electrophoresis (IFE) to characterize the M-protein isotype (IgG, IgA, IgM, light chain, etc.) and quantity, serum free light chain assay (kappa and lambda with ratio), and 24-hour urine SPEP/IFE (UPEP/UIFE) to detect Bence Jones proteinuria. Bone marrow trephine biopsy with immunohistochemistry and flow cytometry confirms clonal plasma cell percentage (greater than or equal to 10% for myeloma). FISH cytogenetics on bone marrow plasma cells for del(17p), t(4;14), t(14;16), t(11;14), and gain(1q) stratifies risk. Whole-body low-dose CT or PET/CT detects lytic bone lesions; whole-body MRI is more sensitive for cord compression and is the preferred imaging in some guidelines. R-ISS (Revised International Staging System) combining ISS stage (albumin, beta-2 microglobulin), FISH cytogenetics, and LDH provides comprehensive prognostic stratification.

Symptomatic multiple myeloma treatment is stratified by transplant eligibility and risk. For transplant-eligible patients, the current standard induction is the quadruplet daratumumab-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) for 4-6 cycles, followed by peripheral blood stem cell collection and autologous SCT. Post-transplant consolidation and lenalidomide maintenance until progression is standard, with the CASSIOPEIA trial supporting daratumumab maintenance. Transplant-ineligible patients receive daratumumab-VRd (VRd) for a defined number of cycles followed by continuous lenalidomide plus dexamethasone maintenance. For relapsed/refractory myeloma: carfilzomib (second-generation PI), pomalidomide (third-generation IMiD), elotuzumab, and daratumumab-containing re-induction regimens are used. Venetoclax (BCL-2 inhibitor) is highly effective in t(11;14)-positive myeloma. BCMA-directed CAR-T therapies (idecabtagene vicleucel, ciltacabtagene autoleucel) achieve remarkable response rates of 70-98% in heavily pre-treated patients. Bispecific T-cell engagers (teclistamab, elranatamab targeting BCMA; talquetamab targeting GPRC5D) provide off-the-shelf alternatives to CAR-T. Zoledronic acid and denosumab prevent skeletal-related events. Radiation for symptomatic solitary lytic lesions.

No established preventive interventions exist for multiple myeloma or MGUS. Population-level screening is not recommended due to the absence of demonstrated mortality benefit, though the iStopMM (Iceland Screens, Treats or Prevents Multiple Myeloma) trial is studying whether MGUS screening and early intervention can alter outcomes. Maintaining a healthy body weight and avoiding occupational exposures to agricultural pesticides and herbicides may modestly reduce risk based on epidemiological data. Patients with established MGUS require structured surveillance with serum SPEP, free light chains, and complete blood count annually or semi-annually (dependent on MGUS risk stratification using the Mayo Clinic model based on M-protein type, size, and free light chain ratio). High-risk MGUS (IgA or IgM type, M-protein greater than 1.5 g/dL, abnormal free light chain ratio) requires more intensive surveillance and earlier bone marrow biopsy. Smoldering myeloma surveillance includes the above plus whole-body imaging annually.

Seek prompt medical evaluation if you experience unexplained bone pain — particularly in the back, ribs, or hips — that is new and persistent, especially if accompanied by fatigue and weight loss. Back pain in an older adult that is constant, unrelated to activity, and associated with new-onset weakness or numbness in the legs requires emergency spine MRI to exclude plasmacytoma or myeloma-related vertebral pathological fracture with cord compression. Unexplained anemia in a patient over 60 years of age should include serum protein electrophoresis and free light chain assay as part of the workup. Recurrent bacterial pneumonia, particularly pneumococcal, in an adult may indicate myeloma-related hypogammaglobulinemia. Patients already diagnosed with MGUS or smoldering myeloma should maintain regular follow-up with a hematologist or myeloma specialist and seek early assessment if they develop new back pain, leg weakness, or deteriorating kidney function — all of which may indicate myeloma progression requiring urgent treatment.

Median OS with modern quadruplet induction and ASCT exceeds 7-8 years. Standard-risk myeloma (no high-risk cytogenetics): median OS exceeds 10 years with modern therapy. High-risk myeloma (del17p, t(4;14)): median OS approximately 4-5 years. MRD negativity after treatment is the strongest predictor of durable remission. CAR-T and bispecific antibodies are transforming outcomes for relapsed/refractory disease. The prognosis for Plasma Cell Neoplasms: Multiple Myeloma, MGUS, and Plasmacytoma varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.